MM patients in the PR group are characterized by high MM proliferation rate and poor clinical outcomes, and increased CHEK1 mRNA levels in this subgroup suggested that CHEK1 could be a biomarker for high-risk MM. This evidence concerns the gene CHEK1 and Miyoshi myopathy.